Por favor, use este identificador para citar o enlazar a este item:
Compartir / Impacto:
|Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL|
Toxic oil syndrome: genetic restriction and immunomodulatory effects due to adulterated oils in a model of HLA transgenic mice
|Autor:||Gallardo, Soledad; Córdoba, Blanca; Posada de la Paz, Manuel; Pozo, Victoria del; Messeguer Peypoch, Ángel; David, Chella S.; Lahoz, Carlos|
|Palabras clave:||Toxic Oil Syndrome|
|Fecha de publicación:||24-jun-2005|
|Citación:||Toxicology Letters 159(2): 173-181 (2005)|
|Resumen:||Toxic oil syndrome (TOS) was described in Spain in 1981, due to the ingestion of contaminated rapeseed oil denatured with 2% aniline. More than 20,000 persons were affected, causing over 2500 deaths. Immunological findings were: eosinophilia, mRNA for Th2 cytokines (IL-4 and IL-5) in lungs, elevated total IgE and sIL-2R and increase of DR2 HLA class II phenotypic frequency in patients died by TOS. Our objective is to test the genetic restriction found in humans using HLA transgenic mice. Results show that mice expressing human DR2 and DQ6 (both in linkage disequilibrium), had higher percentage of eosinophils (DQ6) and IgE (DR2) than other transgenic mice tested (DR3 and DR4). Also, a Th2 shift was found in DR2 transgenic mice when toxic oil was administered with OVA. This has been corroborated by the IL-5 mRNA expression in 4 out of 6 lung tissues from TOS oil treated BALB/c mice.|
These data indicate that an immunological response was induced as consequence of the toxic administration. These results correlate with those found in TOS patients and reinforce the implication of genetic restrictions in the acquisition of toxic-mediated disease.
|Descripción:||9 pages, 3 figures.-- PMID: 15979827 [PubMed].-- Printed version published Nov 15, 2005.|
|Versión del editor:||http://dx.doi.org/10.1016/j.toxlet.2005.05.009|
|Aparece en las colecciones:||(IQAC) Artículos|
Ficheros en este ítem:
No hay ficheros asociados a este ítem.